Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Ro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-11-01
|
| Series: | Kidney Diseases |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/535071 |